Holen Sie sich die Stockscreener-App
26.02
2.01%
-0.58
Schlusskurs vom Vortag:
$26.60
Offen:
$26.87
24-Stunden-Volumen:
107.50K
Relative Volume:
0.25
Marktkapitalisierung:
$480.58M
Einnahmen:
$116.88M
Nettoeinkommen (Verlust:
$-25.09M
KGV:
-185.86
EPS:
-0.14
Netto-Cashflow:
$-20.74M
1W Leistung:
-9.72%
1M Leistung:
-24.05%
6M Leistung:
-31.34%
1J Leistung:
+30.91%
1-Tages-Spanne:
$25.82
$27.16
1-Wochen-Bereich:
$25.82
$29.67
52-Wochen-Spanne:
$15.50
$52.24
Rigel Pharmaceuticals Stock (RIGL) Company Profile
Firmenname
Rigel Pharmaceuticals
Sektor
Branche
Telefon
650-624-1100
Adresse
611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA
Compare RIGL vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RIGL
Rigel Pharmaceuticals
|
26.02 | 491.39M | 116.88M | -25.09M | -20.74M | -0.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.15 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
746.29 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
705.29 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.73 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.42 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Rigel Pharmaceuticals Stock (RIGL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-05 | Hochstufung | Jefferies | Hold → Buy |
| 2023-04-03 | Fortgesetzt | Piper Sandler | Neutral |
| 2022-06-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-06-08 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2022-06-08 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-03-23 | Eingeleitet | B. Riley Securities | Neutral |
| 2020-11-09 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-11-15 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2019-09-26 | Fortgesetzt | JP Morgan | Overweight |
| 2019-03-01 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2018-08-27 | Eingeleitet | Citigroup | Buy |
| 2018-05-02 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2017-12-21 | Fortgesetzt | Piper Jaffray | Overweight |
| 2017-12-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-11-06 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-03-09 | Bestätigt | H.C. Wainwright | Buy |
| 2016-08-31 | Bestätigt | H.C. Wainwright | Buy |
| 2016-08-30 | Bestätigt | Piper Jaffray | Overweight |
| 2016-07-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-06-13 | Eingeleitet | Piper Jaffray | Overweight |
| 2016-04-22 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2013-04-08 | Bestätigt | Stifel | Buy |
| 2012-11-29 | Eingeleitet | UBS | Neutral |
| 2012-11-06 | Bestätigt | Oppenheimer | Outperform |
| 2012-03-26 | Eingeleitet | Canaccord Genuity | Hold |
| 2010-12-10 | Herabstufung | MP Advisors | Outperform → Market Perform |
Alle ansehen
Rigel Pharmaceuticals Aktie (RIGL) Neueste Nachrichten
RIGL stock rises 59% in a year: Time to buy, hold or sell? - MSN
Rigel Pharmaceuticals: Growing Where It Matters (NASDAQ:RIGL) - Seeking Alpha
Rigel Pharmaceuticals (RIGL) earnings expected to grow: Should you buy? - MSN
Assessing Rigel Pharmaceuticals (RIGL) Valuation After Strong Q4 And Full Year 2025 Earnings Results - simplywall.st
Analysts Set Expectations for RIGL Q3 Earnings - MarketBeat
Rigel Pharmaceuticals (RIGL) EPS Spike On Non Cash Gains Challenges Bullish Narratives - Sahm
Rigel Pharmaceuticals’ Fast Track Ambitions Face Significant FDA Uncertainty - The Globe and Mail
Brokers Offer Predictions for RIGL Q1 Earnings - MarketBeat
This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges - AOL.com
Rigel Pharmaceuticals (RIGL) Projects Revenue Decline for 2026 - GuruFocus
Rigel Pharma stock slides on 2026 outlook (RIGL:NASDAQ) - Seeking Alpha
Rigel Pharmaceuticals (NASDAQ:RIGL) Shares Gap DownWhat's Next? - MarketBeat
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Citi Maintains Rigel Pharmaceuticals(RIGL.US) With Buy Rating, Maintains Target Price $71 - 富途牛牛
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Rigel Pharmaceuticals Inc (RIGL) Q4 2025 Earnings Call Highlights: Record Net Income and Strategic Growth Initiatives - GuruFocus
Rigel Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
How The Rigel Pharmaceuticals (RIGL) Story Is Shifting With New Targets And Pipeline Progress - Yahoo Finance
Rigel Pharmaceuticals (RIGL) Set to Report Q4 FY2025 Earnings After the Bell — Here’s What to Expect - AlphaStreet
Cumberland (CPIX) Q4 2025 Earnings Call Transcript - AOL.com
Earnings call transcript: Rigel’s Q4 2025 shows robust growth - Investing.com
Earnings call transcript: Rigel’s Q4 2025 shows robust growth By Investing.com - Investing.com South Africa
Rigel Pharmaceuticals, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:RIGL) 2026-03-03 - Seeking Alpha
RIGL: Record sales and net income in 2025, with strong growth outlook and pipeline progress for 2026 - TradingView
Rigel Pharmaceuticals (RIGL) Q4 Earnings Miss Estimates - Bitget
Rigel Pharma (RIGL) Earnings Call Transcript - AOL.com
Rigel Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Rigel Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Rigel Pharmaceuticals Q4 Earnings, Revenue Rise; 2026 Revenue Outlook Set - marketscreener.com
Rigel Pharmaceuticals (RIGL) Projects FY26 Revenue Growth - GuruFocus
Earnings Summary: Rigel Pharmaceuticals Q4Rigel Pharmaceuticals (NASDAQ:RIGL) - Benzinga
Rigel Pharmaceuticals (NASDAQ:RIGL) Posts Quarterly Earnings Results, Misses Estimates By $0.19 EPS - MarketBeat
RIGL: Record 2025 revenue and net income, with 2026 outlook for continued growth and pipeline progress - TradingView
Rigel Pharmaceuticals reports Q4 EPS $13.54 with items, consensus $1.20 - TipRanks
Rigel (NASDAQ: RIGL) boosts blood cancer drug sales and advances pipeline - Stock Titan
Rigel: Q4 Earnings Snapshot - marketscreener.com
RIGL: Record 2025 revenue and net income, strong product growth, and positive 2026 outlook - TradingView
Rigel Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - marketscreener.com
RIGL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Rigel Pharmaceuticals (RIGL) Set to Announce Q4 Earnings - GuruFocus
A Preview Of Rigel Pharmaceuticals's Earnings - Benzinga
(RIGL) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Implied Volatility Surging for Rigel Pharmaceuticals Stock Options - Nasdaq
Rigel Pharmaceuticals Options See Significant Rise in Implied Volatility - Bitget
Rigel Pharmaceuticals, Inc. (RIGL) Stock Analysis: Unpacking a 49% Potential Upside for Investors - DirectorsTalk Interviews
Walter Moos Sells 4,000 Shares of Rigel Pharmaceuticals (NASDAQ:RIGL) Stock - MarketBeat
Rigel (RIGL) director Moos exercises options and sells 4,000 shares - Stock Titan
Rigel Pharmaceuticals (RIGL) Earnings Expected to Grow: Should You Buy? - Finviz
IOVA vs. RIGL: Which Small-Cap Biotech Has More Upside Potential? - TradingView
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update - The AI Journal
Finanzdaten der Rigel Pharmaceuticals-Aktie (RIGL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):